Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 17 of 17

List	Outcome	Time frame	Description
Primary	Change in Average 24-hour SBP	Baseline and Week 22	Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.
Primary	Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.	Baseline and up to Week 26
Secondary	Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)	Before and at time intervals up to 2 hours post glucose drink at Baseline and Week 22	AUCglucose was calculated based on results of the plasma 2-hour oGTT.
Secondary	Change in Average Diastolic Blood Pressure (DBP)	Baseline and Week 22	Blood pressure was measured by 24-hour ABPM. Daytime average DBP was measured from 06:00 to 21:59. Nighttime average DBP was measure from 22:00 to 05:59.
Secondary	Change in Average Heart Rate (HR)	Baseline and Week 22	Heart rate was measured by 24-hour ABPM. Daytime average HR was measured from 06:00 to 21:59. Nighttime average HR was measure from 22:00 to 05:59.
Secondary	Change in Average Daytime and Nighttime SBP	Baseline and Week 22	Blood pressure was measured by 24-hour ABPM. Daytime average SBP was measured from 06:00 to 21:59. Nighttime average SBP was measure from 22:00 to 05:59.
Secondary	Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline	Baseline and Week 22
Secondary	Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline	Baseline and Week 22
Secondary	Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL	2 hours post glucose drink at Week 22	Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.
Secondary	Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL	2 hours post glucose drink at Week 22	Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.
Secondary	Number of Patients With Any Dose Decrease in Antihypertensive Medication	Baseline and Week 22
Secondary	Number of Patients With Any Dose Decrease in Diabetes Medication	Baseline and Week 22
Secondary	Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication	Baseline and Week 22
Secondary	Number of Patients With Any Dose Increase or Switch in Diabetes Medication	Baseline and Week 22
Secondary	Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%	Baseline and Week 22
Secondary	Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)	Baseline and Week 22	Blood pressure was measured by 24-hour ABPM Test. Reported is the number of patients with HTN at Baseline who achieved SBP \<130 mm Hg at Week 22.
Secondary	Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg	Baseline and Week 22	Blood pressure was measured by 24-hour ABPM. Reported is the number of patients with HTN at Baseline who achieved at least a 5 mm Hg reduction in 24-hour average SBP at Week 22.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04308590/registered

API reference For AI assistants